Pharmaceuticals
-
Novo Nordisk’s new-generation basal insulin Tresiba® approved in China
Sep 27, 2017News Hour: Novo Nordisk today announced that the China Food and Drug Administration (CFDA) has approved Tresiba® (insulin degludec) for the treatment of diabetes in China. Tresiba® is a new-generation, once-daily basal insulin with an ultra-long duration of action which allows... -
Bangladeshi company Beximco started the export of Olopatadine to Canada
Sep 17, 2017News Hour: Beximco Pharmaceuticals Limited (BPL) started the export of Olopatadine, an ophthalmic product for treating the symptoms of eye allergy, to Canada. The BPL today made the announcement following the approval of Olopatadine (0.1% solution)... -
Tresiba® trial shows that people with type 2 diabetes who avoid severe hypoglycaemia have a reduced risk of deat
Sep 16, 2017News Hour: Novo Nordisk announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycemia (low blood sugar levels) are at greater risk of death. The risk... -
Fiasp® significantly improved overall blood sugar control in type 1 diabetes long-term
Sep 15, 2017News Hour: Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting mealtime insulin, improved overall blood sugar and post-meal sugar control over 52 weeks, compared to conventional insulin aspart (NovoRapid®), in new study findings. The findings... -
Chile’s Banmedica SA signed a non-binding agreement to sell all its shares to U.S. based UnitedHealth
Sep 9, 2017News Hour: Chilean healthcare company Banmedica SA told local regulators late on Friday that it had signed a non-binding agreement to sell all its shares to U.S.-based UnitedHealth Group Inc. “If the transaction materializes, the price... -
Two AstraZeneca drugs tackling lung cancer in different ways delivered impressive clinical results
Sep 9, 2017News Hour: Two AstraZeneca drugs tackling lung cancer in different ways delivered impressive clinical results on Saturday, helping the British group offset July’s big clinical trial setback in the disease. Particularly notable was the success of... -
FDA approved Pfizer Inc’s Leukemia drug Mylotarg
Sep 2, 2017News Hour: The U.S. Food and Drug Administration (FDA) on Friday approved Pfizer Inc’s drug, Mylotarg, for certain patients with acute myeloid leukemia (AML). The drug was cleared to treat adults with newly diagnosed AML whose... -
FDA approved a new indication for Victoza® to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes
Aug 31, 2017News Hour: The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza® (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes and established CV... -
Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal
Aug 28, 2017News Hour: Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class... -
FDA approved expanded use of Novo Nordisk diabetes drug to reduce the risk of cardiovascular events
Aug 26, 2017News Hour: Novo Nordisk said on Friday the U.S. Food and Drug Administration (FDA) approved an expanded use of its diabetes drug to reduce the risk of cardiovascular events such as heart attack and stroke. This...
